These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

This long-term agreement will help support the commercialization of VK2735.

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...